{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:07:12Z","timestamp":1724483232666},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>The authors present a case of an 18-year-old man with metastasized osteosarcoma, admitted for methotrexate (MTX) treatment combined with cisplatin and doxorubicin. During the first cycle, severe MTX toxicity was observed with increased MTX serum levels and delayed MTX clearance requiring rescue treatment with intensified leucovorin. In the following cycles, cisplatin and doxorubicin were discontinued, and MTX dose was reduced. The elimination half-life slowly improved over the following cycles suggesting a reversible cause responsible for reduced MTX clearance and toxicity during the first cycle. Cisplatin is well-known for its nephrotoxic effects and can induce reversible tubular injury. Previous treatment with cisplatin may well have been responsible for decreased MTX clearance, and combination treatment should be used with adequate monitoring of MTX levels. Other factors that may have contributed, such as urine alkalization, gene polymorphisms, and other drug\u2013drug interactions are discussed.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000662","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T13:26:25Z","timestamp":1559827585000},"page":"693-695","source":"Crossref","is-referenced-by-count":8,"title":["Reversible Impaired Methotrexate Clearance After Platinum-Based Chemotherapy for Osteosarcoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Thijs","family":"Oude Munnink","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacco","family":"de Haan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Kruchten","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist."},{"key":"R2-20230814","first-page":"1295","article-title":"Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue","volume":"62","author":"Isacoff","year":"1978","journal-title":"Cancer Treat Rep."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/02841860510029770","article-title":"High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results","volume":"44","author":"Comandone","year":"2005","journal-title":"Acta Oncol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1093\/ndt\/gfn503","article-title":"Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs","volume":"23","author":"de Miguel","year":"2008","journal-title":"Nephrol Dial Transpl."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1248\/bpb.b14-00362","article-title":"Nephrotoxicity induced by piperacillin\u2013tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia","volume":"37","author":"Karino","year":"2014","journal-title":"Biol Pharm Bull."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/pbc.24720","article-title":"Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population","volume":"61","author":"Pratt","year":"2014","journal-title":"Pediatr Blood Cancer."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int J Pharm."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.taap.2016.06.030","article-title":"P-gp, MRP2 and OAT1\/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate","volume":"306","author":"Jia","year":"2016","journal-title":"Toxicol Appl Pharmacol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00280-004-0797-y","article-title":"Late-onset delayed excretion of methotrexate","volume":"54","author":"Pauley","year":"2004","journal-title":"Cancer Chemother Pharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jcph.1252","article-title":"A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006\/Sarcoma-09 trial","volume":"58","author":"Lui","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1998.16.2.658","article-title":"Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin","volume":"16","author":"Bacci","year":"1998","journal-title":"J Clin Oncol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/cncr.20152","article-title":"High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma","volume":"100","author":"Crews","year":"2004","journal-title":"Cancer."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J Nephrol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","article-title":"Renal drug transporters and drug interactions","volume":"56","author":"Ivanyuk","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","article-title":"MW\/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring","volume":"22","author":"Proost","year":"1992","journal-title":"Comput Biol Med."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:20:40Z","timestamp":1692051640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000662","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}